By Aayush Khanna Aurobindo Pharma Ltd. (NS:ARBN) celebrates a significant milestone as its wholly owned subsidiary, Eugia Pharma Specialities Limited, secures final approval from the US...
Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 60471.79 Crore) operating in Pharmaceuticals sector.
Top stock picks for today: In an interaction with BT TV, Mileen Vasudeo said SBI Life Insurance Company Ltd's share price could head higher in the near term. For SBI Life, he said, "One can...
This space articulates PV Ramprasad Reddy’s journey from a clerk to the co-founder of Aurobindo Pharma.
An analyst from Citi maintained Aurobindo Pharma (NS: ARBN) at 'sell' with a price target of ₹820.00 from a prior price target of %currency%%price%. Prior to this rating, Aurobindo...
An analyst from Bernstein maintained Aurobindo Pharma (NS: ARBN) at 'market perform' with a price target of ₹980.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Goldman Sachs maintained Aurobindo Pharma (NS: ARBN) at 'buy' with a price target of ₹1.07K from a prior price target of %currency%%price%. Prior to this rating,...
Despite the weakness in the market, 6 large and midcap stocks managed to hit new 52-week highs on November 10.
Stocks to watch out for today: Tata Motors, Aurobindo Pharma, Suven Pharma, Ashok Leyland, Piramal Enterprises and more
Aurobindo Pharma on Thursday reported 84% year-on-year (YoY) rise in net profit to Rs 752 crore in the second quarter ended September 2023, led by strong sales from the US market.
Since the start of this financial year (FY24), the stock of Aurobindo Pharma has been one of the top pharma gainers, enhancing investor wealth by over 68 per cent, with a third of those...
Lucknow, Oct 25 (IANS) The Uttar Pradesh government will develop the Lalitpur bulk drug park and has set aside Rs 1,000 crore for the same. It hopes to attract an investment of Rs one lakh...
This S&P BSE 200 Stock has announced the inauguration of a new plant that will be commissioned for production by Q4 FY24. The company has a market cap of Rs. 53,813 crore and is 1%...
The analysis revealed seven stocks which were held by mutual funds across more than 100 schemes as of the last month, and have given high returns in 2023. Of the 7 stocks, four stocks have...
An analyst from Goldman Sachs maintained Aurobindo Pharma (NS: ARBN) at 'buy' with a price target of INR1,000.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Macquarie maintained Aurobindo Pharma (NS: ARBN) at 'outperform' with a price target of INR1,000.00 from a prior price target of %currency%%price%. Prior to this rating,...
Sun Pharmaceutical Industries and Aurobindo Pharma are recalling products from the US market due to manufacturing issues. Sun Pharma's subsidiary is recalling 69,707 cartons of Cequa, used...
Dalmia Bharat, Axis Securities said, demonstrated a strong breakout from its medium-term "Rounded-Bottom" pattern at the level of Rs 2,280 on the weekly chart in the early September.
Stocks to watch out for today: JSW Infrastructure, Coal India, Ramkrishna Forgings, Karur Vysya Bank, Hero MotoCorp, Rail Vikas Nigam, Aurobindo Pharma and more
An analyst from Citi downgraded Aurobindo Pharma (NS: ARBN) from 'buy' to 'sell' with a price target of INR750.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from PhillipCapital downgraded Aurobindo Pharma (NS: ARBN) from 'buy' to 'neutral' with a price target of INR900.00 from a prior price target of %currency%%price%. Prior to...
An analyst from ICICI Securities maintained Aurobindo Pharma (NS: ARBN) at 'add' with a price target of INR920.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Kotak downgraded Aurobindo Pharma (NS: ARBN) from 'add' to 'sell' with a price target of INR775.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Investec maintained Aurobindo Pharma (NS: ARBN) at 'buy' with a price target of INR1055.00 from a prior price target of %currency%%price%. Prior to this rating, Aurobindo...
An analyst from HSBC maintained Aurobindo Pharma (NS: ARBN) at 'hold' with a price target of INR855.00 from a prior price target of %currency%%price%. Prior to this rating, Aurobindo...
An analyst from Prabhudas Lilladher maintained Aurobindo Pharma (NS: ARBN) at 'accumulate' with a price target of INR900.00 from a prior price target of %currency%%price%. Prior to this...
An analyst from Elara Securities India maintained Aurobindo Pharma (NS: ARBN) at 'accumulate' with a price target of INR949.00 from a prior price target of %currency%%price%. Prior to...
Shares of the largest Indian player in the US generic drug industry jumped nearly 6.5 percent in early trade and reached a 52-week high of Rs 834.80 on July 27 after the business announced...
By Malvika Gurung Investing.com -- Shares of the pharmaceutical manufacturer Aurobindo Pharma (NS:ARBN) hit a new 52-week high of Rs 796.5 apiece in Wednesday’s intraday trade after the...
An analyst from Elara Securities India maintained Aurobindo Pharma (NS: ARBN) at 'accumulate' with a price target of INR800.00 from a prior price target of %currency%%price%. Prior to...
An analyst from HSBC maintained Aurobindo Pharma (NS: ARBN) at 'hold' with a price target of INR610.00 from a prior price target of %currency%%price%. Prior to this rating, Aurobindo...
An analyst from PhillipCapital maintained Aurobindo Pharma (NS: ARBN) at 'buy' with a price target of INR710.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Investec maintained Aurobindo Pharma (NS: ARBN) at 'buy' with a price target of INR710.00 from a prior price target of %currency%%price%. Prior to this rating, Aurobindo...
An analyst from ICICI Securities upgraded Aurobindo Pharma (NS: ARBN) from 'hold' to 'add' with a price target of INR655.00 from a prior price target of %currency%%price%. Prior to this...
An analyst from BofA Securities maintained Aurobindo Pharma (NS: ARBN) at 'buy' with a price target of INR725.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Citi maintained Aurobindo Pharma (NS: ARBN) at 'buy' with a price target of INR660.00. Prior to this rating, Aurobindo Pharma had 20 buy ratings, 6 hold ratings, and 1...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
